SOLID TUMORS

This early-stage study tests a new drug, DPTX3186, in 40 adults with advanced solid tumors (like colorectal or lung cancer) that have a specific genetic change (Wnt pathway) and no standard treatments left. The main goals are to check safety and how the drug moves through the bod…

This study tests a personalized vaccine made from a patient's own tumor mutations. It aims to help the immune system recognize and attack cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal is to see if th…

This study tests an experimental drug called JAB-30355 in adults with advanced solid tumors that have a specific TP53 Y220C mutation. The main goals are to check safety and find the right dose, while also seeing if the drug can shrink tumors. About 144 participants who have alrea…

This early-stage study tests a new drug, XB371, in about 150 adults whose solid tumors have spread or come back. The main goal is to check the drug's safety and find the right dose. Researchers will also measure how the drug behaves in the body.

This early-phase study tests a new drug called HDM2017 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also looking at how the drug moves through the body and wh…

This early-phase trial tests a new oral drug, Aza-TdC, in adults with advanced solid tumors that have not responded to standard treatments. The drug aims to 'turn back on' genes that may slow tumor growth. The main goals are to check safety and find the best dose.

This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have lost a gene called MTAP. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 40 adults will receive PEP08 alone or with another cance…

This study tests a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. This is an early-stage trial, so it focuses on safety a…

This early-phase study tests a new drug called INCA036873 in 280 adults with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The main goal is to check the drug's safety and find the right dose. Participants will be closely monitored for…

This study looks at the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in people who have already been taking it in earlier studies. It is for adults with solid tumors or blood cancers who are either still on treatment or in follow-up. Participants…

This study tests a new drug called 7MW4911 in 200 people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an early-stage trial, so the focus is on safety an…

This study tests a new drug called ABL103, given with the immunotherapy pembrolizumab and sometimes a chemotherapy (taxane), for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink or …

This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then, refining that dose; and finally, checking how well the drug shrinks tumors. All participants receive the…

This early-phase study tests a new radioactive drug, lutetium [177Lu] BL-ARC001, in 22 adults with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must ha…

This study tests a new drug called SOA101, a special antibody that targets cancer cells and helps the immune system attack them. It is for people with advanced solid tumors (like lung, ovarian, head and neck, breast, or colorectal cancer) who have no other good treatment options.…

This early-phase study tests an experimental drug called INCB123667, alone or with other cancer treatments, in people with advanced solid tumors that have stopped responding to standard care. The main goals are to find safe doses and check for side effects. About 604 adults will …

This study tests a new treatment called B7H3 CAR-T cell therapy for people with advanced solid tumors that have a specific marker (B7H3). The therapy uses the patient's own immune cells, modified in a lab to better find and kill cancer cells. About 20 participants will receive th…

This early-stage trial is testing a new cell therapy called GK01, given alone or with chemotherapy, in 15 people with advanced solid tumors like pancreatic or stomach cancer. The main goal is to check safety and how the body handles the treatment. Researchers will also look for s…

This early-stage study tests a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Researchers will also monitor side effects and how long any …

This study tests a new drug called SHR-4610 in people with advanced solid tumors that have not responded to standard treatments or have no standard treatment available. The trial has two parts: first to find a safe dose, then to see if the drug can shrink tumors or slow their gro…

This study tests a new drug called S-531011, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About 282 adults wil…

This early-stage study tests a new drug, QTX3034, in 250 people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to check the drug's safety and find the right dose, either alone or with another drug called cetuximab. Participants m…

This early-phase study tests a new oral drug, TYRA-430, in people with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find the safest dose and check for side effects. About 100 adults will take part. This i…

This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney injury in people receiving platinum-based chemotherapy for solid tumors. About 46 participants will receive either dapagliflozin or a placebo, and researchers will measure kidney damage markers i…

This early-phase study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find the highest safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703…

This study tests an experimental drug called ZL-1310 in about 112 adults with advanced neuroendocrine carcinomas (a type of solid tumor) that have worsened after standard chemotherapy. The main goals are to check safety and see if the drug can shrink tumors. Participants must hav…

This early-phase study tests a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to check safety, find the right dose, a…

This study tests a new drug, BI 3923948, in people with advanced solid tumors that have spread and are hard to treat. About 60 adults will receive the drug alone or with an immunotherapy (checkpoint inhibitor) to find the safest dose and see if it shrinks tumors. The drug is inje…

This early-stage study tests a new drug, INCB161734, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to check the drug's safety and find the right dose, either alone or with other cancer treatments. About 710 adults whos…

This early-phase study tests a new treatment called TX103 CAR-T cells in 85 adults with advanced solid tumors that have not responded to standard therapy. The therapy uses a patient's own immune cells, modified to target a protein (B7-H3) on cancer cells. The main goals are to ch…

This early-phase study tests a new drug called AB521 (casdatifan) in people with advanced kidney cancer or other solid tumors that have not responded to standard treatments. The study will first find a safe dose of AB521 alone, then test it alone or combined with other cancer dru…

This study tests a drug called FORE8394 (plixorafenib) in people with advanced solid tumors or brain tumors that have specific BRAF gene changes. The goal is to see if the drug can shrink tumors or slow their growth. About 254 participants aged 10 and older will take the pill and…

This study tests a drug called eflapegrastim in children with solid tumors or lymphoma who are receiving chemotherapy. The goal is to see if it safely helps their white blood cell counts recover faster, reducing the risk of severe infections. About 40 children will take part, and…

This study aims to find out if certain substances in the blood, called interferons, can predict serious side effects from cancer immunotherapy. Researchers will collect blood samples from 300 cancer patients starting immunotherapy and 40 people with autoimmune diseases like lupus…

This study looks at gene changes (mutations) in cancer cells from people with solid tumors or blood cancers. Researchers use leftover tumor tissue from past surgeries or biopsies, plus a blood or saliva sample, to find mutations that might affect how a cancer responds to treatmen…